Objectives: We performed a post hoc analysis of outcome in patients with, versus those without, calcified target lesions from the BASE ACS trial. Background: The outcome of contemporary stent implantation in patients with calcified lesions presenting with acute coronary syndrome is unknown. Methods: The BASE ACS trial randomized 827 patients (1:1) presenting with acute coronary syndrome to receive either titanium-nitride-oxide-coated stents or everolimus-eluting stents. Calcified lesions were defined as moderate or severe calcification in the vessel wall by coronary angiography. The primary endpoint was major adverse cardiac events (MACE): a composite of cardiac death, non-fatal myocardial infarction or ischemia-driven target lesion revascularization. Follow-up was planned at 12 months, and yearly thereafter for up to 7 years. Results: Of 827 patients enrolled in the trial, 352 (42.6%) had calcified target lesions. Median follow-up was 5.0 years. The incidence of MACE was higher in patients with, versus those without, calcified target lesions (19.6% vs. 12.2%, respectively, P ¼ 0.004). This was driven by more frequent cardiac death and non-fatal myocardial infarction events (P < 0.05, both). The rates of ischemia-driven target lesion revascularization were comparable (P > 0.05). MACE and the other endpoints were comparable between the 2 propensity-score matched subgroups (P > 0.05 for all). Hypertension and smaller vessel size independently predicted MACE in patients treated for calcified lesions. Conclusions: Patients presenting with acute coronary syndrome who were treated for calcified lesions had worse long-term clinical outcome, compared with those treated for non-calcified lesions, mainly due to more frequent safety events. In the propensity score-matched analysis, the outcome was comparable. (J Interven Cardiol 2017;30:114-123) 
Introduction
Patients with calcified coronary lesions represent a particularly challenging subset. In the bare-metal stent era, extensive lesion calcification was associated with more peri-procedural myocardial infarction (MI). 1 Prior reports demonstrated that first-generation drugeluting stents were associated with a better efficacy outcome in calcified lesions, versus bare-metal stents, at mid-term follow-up; safety outcome was comparable. [2] [3] [4] However, in patients treated with sirolimus-eluting stents, calcified lesions were still associated with worse angiographic restenosis, and target lesion revascularization (TLR), versus noncalcified lesions. 5 Moreover, in pooled data from 2 large randomized trials in patients with acute coronary syndrome, lesion calcification was associated with worse efficacy and safety outcome at 1 year. 6 The outcome of second-generation DES in patients with calcified lesions remains unclear.
The safety of titanium-nitride-oxide-coated bioactive stents (BAS) was demonstrated in unselected cohorts, 7, 8 and in randomized trials of patients with acute coronary syndrome. 9, 10 The randomized BASE ACS trial showed non-inferiority of BAS versus everolimus-eluting stents (EES), for the primary endpoint of major adverse cardiac events (MACE) in patients with ACS, at 12-month, 2-year, and long-term follow-up. [10] [11] [12] Calcified target lesions predicted 12-month MACE in the BASE ACS trial. 10 So far, the comparative outcome of BAS versus EES in patients with calcified lesions presenting with acute coronary syndrome is unknown. In a post hoc analysis, we explored the long-term clinical outcome of the BASE ACS trial in patients with calcified target lesions.
Methods
Patient Selection and Study Design. The trial design was previously described. 10 In short, the BASE ACS trial was a prospective single-blinded randomized trial conducted in 14 centers. From January 2009 to September 2010, we randomized 827 patients (1:1) presenting with acute coronary syndrome who underwent early percutaneous coronary intervention to receive either BAS (Titan-2 1 , Hexacath, Paris, France) or EES (Xience V 1 , Abbott Vascular, Santa Clara, CA, USA). Follow-up was planned at 12 months, and yearly thereafter through 7 years.
Ethical Issues. The trial was initiated by the investigators and conducted according to the ethical guidelines of the 1964 Declaration of Helsinki, as revised in 2013. Informed written consent was obtained from every patient after explanation of the trial protocol; the protocol was approved by the ethics committees of the coordinating center and the other participating centers. The trial is registered with ClinicalTrials.gov, number NCT00819923.
Pharmacological Interventions. Patients not previously maintained on aspirin were pretreated with aspirin at a loading dose of 250 mg orally or 250-500 mg intravenously, and continued at a dose of 75-150 mg daily indefinitely. Oral clopidogrel was initiated at a loading dose of 300-600 mg before or immediately after the procedure and continued at a dose of 75 mg daily. Patients in either group were prescribed clopidogrel for a minimum of 6 months, and thereafter, for extended periods (maximum 12 months) at operator's discretion. During the procedure, lowmolecular-weight or unfractionated heparin was administered intravenously in the standard dosage. Use of glycoprotein IIb and IIIa inhibitors or bivalirudin was left to operator's discretion.
Definitions and Study Endpoints. Calcified target lesions were defined based on the presence of moderate or severe calcification in the vessel wall by coronary angiography. Moderate calcification was defined as radio-opaque densities seen only during the cardiac cycle (but not in still frames) before contrast injection, usually on 1 side of the vessel wall. Severe calcification was defined as radio-opaque densities seen without cardiac motion before contrast injection, usually on both sides of the vessel wall. 6 Patients with mild or no target lesion calcification were classified together into 1 group (no calcification). 6 The diagnostic criteria for non-ST-segment elevation acute coronary syndrome and ST-segment elevation MI were previously described. 10 The primary endpoint was the first occurrence of MACE: a composite of cardiac death, non-fatal MI, or ischemia-driven TLR. Secondary endpoints included non-cardiac death, and definite stent thrombosis (ST). Cardiac death was defined as death from cardiovascular causes or any death without known cause. ST was adjudicated according to the criteria of definite ST described by the Academic Research Consortium. 13 An independent clinical events committee whose members were blinded to stent group allocation adjudicated all the individual endpoints according to the prespecified definitions.
Statistical Analysis. Continuous variables were presented as mean AE standard deviation, whereas categorical variables were described with absolute and relative (percentage) frequencies. Comparisons between the 2 subgroups (patients with and those without calcified lesions) were performed using the unpaired t-test for continuous variables, and the Pearson chi-square test or Fisher's exact test for categorical variables, as appropriate. Data analysis was based on the intention-to-treat principle. We observed significant, differences between the 2 subgroups in several baseline characteristics. Therefore, we performed a propensity score-matched analysis of the 2 subgroups in order to estimate the impact of target lesion calcification on the clinical 
Results
Baseline Clinical, Angiographic, and Procedural Data. Of the 827 patients enrolled in the BASE ACS trial, 352 (42.6%) had calcified target lesions. Median follow-up duration was 5.0 years; mean (SD) 4.2 (1.9) years. Compared with those treated for non-calcified lesions, patients treated for calcified lesions were older, had more often coronary risk factors, prior coronary events, peripheral vascular, and cerebrovascular disease; they had larger vessels, longer and more complex lesions (P < 0.05 for all). They underwent more often pre-and post-dilation, and received longer stents (P < 0.05 for all). No debulking procedure was performed in either group. The baseline clinical, angiographic, and procedural data are summarized in Table 1 .
Long-Term Clinical Outcome in Crude Subgroups. The cumulative incidence of MACE at longterm follow-up was higher in patients with, versus those without, calcified lesions (19.6% versus 12.2%, respectively, P ¼ 0.004) ( Table 2 and Fig. 1 ). This was driven by more frequent cardiac death and non-fatal MI events (5.1% versus 1.7%, and 9.1% versus 5.1%, P ¼ 0.005 and P ¼ 0.02, respectively). The rates of ischemia-driven TLR were comparable (P > 0.05). Definite ST and non-cardiac death occurred more often in patients with calcified lesions (P < 0.05 both) ( Table 2) .
Long-Term Clinical Outcome in Matched Subgroups. Propensity score matching yielded 466 patients (233 pairs) with balanced baseline characteristics (Table 3 ). In the propensity score-matched pairs, MACE and all the individual endpoints were comparable between the 2 matched subgroups (P > 0.05 for all) (Table 4) .
Stent-Based Analysis of the Two Subgroups. In patients treated for calcified lesions, the incidence of MACE was comparable between the 2 stent arms (15.8% versus 23.7%, for BAS versus EES, respectively, P ¼ 0.06). Definite ST occurred less frequently with BAS versus EES (1.1% versus 5.9%, respectively, P ¼ 0.013). In this patient subgroup, 10 definite ST events occurred in patients who received EES at longterm follow-up. These included 5 early events (30 days), 1 late event (30 days to 1 year), and 4 very late events (1 year through 7 years). The other endpoints were comparable (P > 0.5 for all) ( Fig. 2A) . Comparably, in patients treated for non-calcified lesions, MACE and all the individual endpoints were comparable between the 2 stent arms (P > 0.5 for all) (Fig. 2B) .
Analysis of Adverse Outcome in the Subgroup With Calcified Lesions. In univariate analyses, the variables associated with MACE in the subgroup with calcified target lesions were age (P ¼ 0.021), hypertension (P < 0.001), diabetes (P ¼ 0.018), and smaller reference vessel diameter (P ¼ 0.005), with a trend toward association with hypercholesterolemia (P ¼ 0.072), prior MI (P ¼ 0.051), and stent type (P ¼ 0.065). In multivariable analysis, the independent predictors of MACE were hypertension (hazard ratio 2.77, 95% confidence interval 1.56-4.91, P < 0.001), and smaller reference vessel diameter (hazard ratio 0.43, 95% confidence interval 0.24-0.76, P ¼ 0.003). 
Discussion
Main Findings. The current post hoc analysis of the BASE ACS trial demonstrated that patients presenting with acute coronary syndrome who were treated for calcified lesions had worse long-term clinical outcome, compared with those treated for noncalcified lesions, mainly due to more frequent safety events (cardiac death and non-fatal MI); yet, the outcome was comparable in the propensity scorematched subgroups. Hypertension and smaller vessel size independently predicted MACE in patients treated for calcified lesions. Moreover, the long-term clinical outcome of BAS was comparable to that of EES in patients treated for calcified and those treated for noncalcified lesions. The current report is the first to demonstrate the comparative outcome of BAS versus EES in patients with acute coronary syndrome treated for calcified lesions.
Prevalence of Calcified Lesions in Patients Undergoing Percutaneous Coronary Intervention. The current analysis of the BASE ACS trial demonstrated a high prevalence of target lesion calcification in patients undergoing percutaneous coronary intervention for acute coronary syndrome (42.6%). This is contrary to the previous observations that culprit lesions in acute coronary syndrome are usually soft, lipid-rich, and less likely calcified. 14 Indeed, most prior randomized controlled trials which explored the outcome of first-generation drug-eluting stents have deliberately excluded patients with "significant" calcification of the target lesion-as assessed by the operator. In more recent all-comer trials of second-generation drug-eluting stents, patients with calcified target lesions ranged from 13% to 33%. [15] [16] [17] Comparably, in pooled data from 2 large randomized trials of patients with acute coronary syndrome (47.7% ST elevation MI), 29.4% of lesions treated were moderately or severely calcified, as assessed by an independent angiographic core lab. 6 The higher prevalence of calcified target lesions in the current report might be due to the inclusion of some patients with mild calcification in the subgroup with calcified lesions.
Outcome of Percutaneous Coronary Intervention in Calcified Lesions. Evidence from 2 pooled patient-level analyses of contemporary large randomized trials and 1 small observational study supported that patients treated for calcified lesions consistently have worse angiographic and clinical outcome, compared with those treated for non-calcified lesions. 5, 6, 18 Interestingly, moderate or severe calcification of the target lesion independently predicted both the safety and efficacy outcome at long-term follow-up in the 2 pooled analyses 6, 18 Similarly, calcified target lesions independently predicted MACE in the original report of the BASE ACS trial at 12-month follow-up. 10 Conversely, reports from post hoc analysis of a randomized trial and a post-marketing registry (both first-generation drug-eluting stents) demonstrated comparable outcome of patients with and without calcified lesions who received drug-eluting stents. 3, 19 In the pooled analysis of 7 randomized trials, 43% of patients received second-generation drug-eluting stents 18 ; in the other reports, first-generation drugeluting stents were used. 3, 5, 6, 19 Data are still lacking on the outcome of second-generation drug-eluting stents in calcified lesions. Interestingly, in the current report, both the safety and efficacy outcomes were comparable in the matched subgroups (with and without calcified target lesions). It seems that the higher-risk profile of patients with calcified target lesions-such as older age, more frequent atherosclerosis risk factors, and more frequent prior vascular disease/events-was largely responsible for their worse clinical outcome. Therefore, target lesion calcification might have been a marker of poor prognosis in the current report, rather than bearing a direct cause-effect relationship with worse outcome. The incidence of definite ST in patients who received EES for calcified target lesions was high, compared with prior reports form unselected cohorts who received EES. Half the definite ST events (5 events) in these patients occurred early during the first month following the index procedure: at a time when all the patients were maintained on dual antiplatelet therapy with aspirin and clopidogrel. In the original report of the BASE ACS trial, early ST associated with EES was high (1.7%: 3 cases acute ST, 4 cases subacute ST). 10 Possible underlying mechanisms of early ST after EES include initial TIMI flow grade 0/1, high thrombus burden, and procedural factors such as stent undersizing, edge dissection, and periprocedural use of bivalirudin. 10 Initial TIMI flow grade 0/1 (observed in 6 out of 7 cases of early ST after EES) was an independent predictor of early ST in a post hoc analysis of the HORIZONS AMI trial. 20 Additionally, periprocedural bivalirudin (used in 2 out of 3 cases of acute ST after EES) was associated with high rates of acute ST in patients with ST-elevation MI undergoing primary percutaneous coronary intervention in the HORIZONS AMI trial. 21 Mechanisms of Poor Outcome in Calcified Lesions. The exact mechanisms underlying the worse outcome of percutaneous coronary intervention in patients with versus those without calcified target lesions are still unclear. In severely calcified lesions, stent underexpansion is common, and portends a high risk of ST and restenosis following implantation of first-generation drug-eluting stents. 22, 23 Indeed, in a pooled analysis of 2 large randomized trials in patients with acute coronary syndrome (47.7% ST elevation MI, 80% drug-eluting stents), separation of the event curves (safety and efficacy outcomes) between patients with and without calcified lesions occurred early in the first month after the procedure; the curves continued parallel through 12 months, suggesting that the difference was mainly due to procedure-related events. 6 Nevertheless, in a pooled analysis of 7 large randomized trials (53.2% acute coronary syndrome, 43% second-generation drug-eluting stents and the rest first-generation drug-eluting stents), the event curves continued to separate between the 2 subgroups (with and without calcified lesions) after 12 months (in landmark analysis) through 3 years of follow-up, indicating that the worse outcome in patients with calcified lesions is not only mediated by periprocedural complications. 18 Expectedly, in the current report, both predilatation and postdilatation were performed more frequently in patients with calcified target lesions. By protocol, both predilatation and postdilatation were left to operator's discretion. The curves of MACE for the 2 subgroups separated as early as the first month post-procedural, again speaking of procedure-related complications; yet, separation of the curves continued through 2 years, denoting other events unrelated to the procedure. However, neither predilatation nor postdilatation correlated with MACE in the subgroup with calcified target lesions in univariate analysis. Another potential explanation is that coronary calcification is a surrogate of more diffuse/extensive atherosclerotic vascular disease. Prior studies by electron-beam computerized tomography showed that coronary artery calcification was associated with a higher incidence of cardiovascular disease events in patients with chest pain, as well as high-risk hypertensive patients. 24, 25 Actually, patients with calcified target lesions in the current study had more frequent prior coronary and cerebrovascular events, more often peripheral arterial disease, and more frequent atherosclerotic risk factors. Moreover, on-clopidogrel platelet reactivity correlated positively with increased coronary calcification as visualized by intravascular ultrasound. 26 This might portend a higher risk of safety outcome. Additionally, difficulty to advance the stent across heavily calcified lesions might lead to damage to the polymer coating of drug-eluting stents, as was previously demonstrated with scanning electron microscopy; this distorts the release of antiproliferative drug, and promotes neointimal hyperplasia/ST. 27 Finally, some genetic loci were strongly associated with both coronary artery calcification and incident MI events. 28 Limitations of the Study. The BASE ACS trial was not designed a priori to particularly explore specific differences in outcome based on target lesion calcification. Due to the retrospective nature of this post hoc analysis, some data relevant to the outcome might have been missed. In addition, the trial may be underpowered for specific subgroup analysis. Moreover, analysis of patient data in 1 subgroup with different stent designs should also be interpreted with caution. Finally, the current post hoc analysis was a non-randomized subgroup analysis; this might limit the conclusiveness of the results.
Conclusion
Patients presenting with acute coronary syndrome who were treated for calcified lesions had worse longterm clinical outcome, compared with those treated for non-calcified lesions, mainly due to more frequent safety events (cardiac death and non-fatal MI); yet, the outcome was comparable in the propensity scorematched subgroups. The long-term clinical outcome of BAS was comparable to that of EES in patients treated for calcified and those treated for non-calcified lesions.
